CORRIGENDUM

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

E Terpos, E Kastritis, M Roussou, D Heath, D Christoulas, N Anagnostopoulos, E Eleftherakis-Papaiakovou, K Tsionos, P Croucher and MA Dimopoulos

Leukemia (2008) 22, 2292; doi:10.1038/leu.2008.288

Correction to: *Leukemia* (2008) **22,** 2247–2256; doi:10.1038/ leu.2008.235; published online 4 September 2008

The correct figure and legend are shown here.

The authors apologize for any inconvenience caused.

Since the publication of the above article, the authors have identified an error in the legend of Figure 4.




Figure 4 Survival according to soluble receptor activator of nuclear factor- κ B ligand/osteoprotegerin (sRANKL/OPG ratio; –, above median; –, below median).

